Exscientia (NASDAQ:EXAI) Shares Gap Down – Should You Sell?

Exscientia plc (NASDAQ:EXAI)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $5.21, but opened at $5.09. Exscientia shares last traded at $5.11, with a volume of 18,248 shares changing hands.

Wall Street Analyst Weigh In

EXAI has been the topic of a number of analyst reports. TD Cowen restated a “hold” rating on shares of Exscientia in a research report on Friday, August 9th. Barclays reissued an “equal weight” rating and set a $5.00 target price on shares of Exscientia in a research note on Tuesday, August 13th.

Exscientia Stock Performance

The company has a 50-day simple moving average of $5.14 and a two-hundred day simple moving average of $5.06. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.93 and a current ratio of 5.93. The firm has a market capitalization of $603.23 million, a P/E ratio of -3.98 and a beta of 0.84.

Exscientia (NASDAQ:EXAI) last announced its earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). The business had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. As a group, equities analysts forecast that Exscientia plc will post -1.25 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Novo Holdings A S bought a new position in shares of Exscientia in the second quarter worth about $66,742,000. Bank of New York Mellon Corp grew its holdings in Exscientia by 108.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after buying an additional 202,377 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Exscientia during the second quarter valued at approximately $256,000. EntryPoint Capital LLC lifted its holdings in shares of Exscientia by 22.8% in the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after buying an additional 5,784 shares in the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of Exscientia during the second quarter worth $115,000. 41.58% of the stock is owned by institutional investors.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.